Phaseline

Companies › NGM Biopharmaceuticals

NGM Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NGM120
Gdf15 analog
–Phase 2Colorectal CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07033026NGM120Phase 2Colorectal CancerOncologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.